08:55 AM EDT, 10/21/2025 (MT Newswires) -- GSK (GSK) said Tuesday the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending a marketing authorization for the prefilled syringe presentation of Shingrix, a vaccine used in adults to protect against shingles.

The company said the committee's opinion was based on data showing that the prefilled syringe is technically comparable to the current presentation of the vaccine.

The European Commission is expected to render a decision in December, GSK said.

The vaccine is currently available in two vials, one containing lyophilised powder antigen and another a liquid adjuvant, which are combined prior to administration, GSK said, adding that a prefilled syringe would simplify administration of the vaccine.

Shingrix has been authorized in the European Union since 2018 for adults 50 years and older, and since 2020 for adults 18 and older at increased risk of herpes zoster, GSK said.